UBE3A and Angelman syndrome: Conversely, the loss of or reduction in E6AP’s expression leads to Angelman syndrome (AS), clinically described by speech anomalies, delayed motor development and function, and the occurrence of frequent, repetitive epileptic seizures [68,71,72,73].